The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...
This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...
Orbis emerged from stealth in February 2024 with $28.1 million in seed funding. The Danish biotech, which aims to flip ...
Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...
A larger body doesn’t necessarily mean you have ‘clinical obesity’, according to a proposed new definition of the disease.
A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...
Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...
Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback